PURCHASE, N.Y., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways (the "Company" or "Cognition"), announced that Lisa Ricciardi, Chief Executive Officer, will deliver a company presentation at the H.C. Wainwright Annual Global Investment Conference and participating on a panel at the Cantor Fitzgerald Global Healthcare Conference in September 2023. In addition, she will be moderating a panel on pipeline prioritization strategies at the Longwood Healthcare Leaders Fall Conference, a brainstorming forum of pharmaceutical, healthcare and investment leaders focused on accelerating the translation of discoveries into medicines.
Presentation Details:
H.C. Wainwright Annual Global Investment Conference
Dates: September 11-13, 2023
Presentation Day/Time: September 13 at 4:00 pm
Location: Kennedy II, Lotte New York Palace, New York
Live webcast will be available on the events and presentations section of Cognition's IR site during the event
Longwood Healthcare Leaders Fall Conference
Dates: September 18-19, 2023
Presentation Day/Time: September 19 at 4:10pm
Location: Harvard Medical School, Boston
Cantor Fitzgerald Global Healthcare Conference
Dates: September 26-28, 2023
Presentation Day/Time: September 26 at 9:20 am
Location: Intercontinental Barclay Hotel, New York
Live webcast will be available on the events and presentations section of Cognition's IR site during the event
About Cognition Therapeutics:
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimer's disease, dementia with Lewy ...